A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- DP303c
- Conditions
- HER2-positive Advanced Solid Tumors
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Area Under Curve from t 0 to the infinity (AUC0-inf)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a study of DP303c in patients with HER2-positive advanced solid tumors.
Detailed Description
This is a multi-center, single-arm Phase I study to evaluate the pharmacokinetic profile, safety, and initial efficacy of DP303c in patients with HER2-positive advanced solid tumors. Patients will be treated with DP303c injection at 3.0 mg/kg every 3 weeks. Patients will receive DP303c until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Voluntary agreement to provide written informed consent;
- •Age ≥ 18 years and older;
- •Patients with advanced solid tumors confirmed by histology or cytology;
- •Received at least 1 line of systemic anti-HER2 therapy or refused systemic therapy for advanced disease states;
- •Confirmed to be HER2 positive by local lab;
- •The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Life expectancy ≥ 3 months;
- •Adequate functions of major organs;
- •Female and male patient of childbearing age must agree to take adequate contraceptive measures during the entire study period and through at least 6 months after the last dose of study drug.
Exclusion Criteria
- •Pregnant or breastfeeding women;
- •Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to NCI CTCAE 5.0) (except for adverse reaction judged by investigators such as alopecia, laboratory tests, etc.);
- •History of LVEF \< 40%, symptomatic congestive heart failure (CHF), or associated toxicity leading to permanent discontinuation during previous anti-HER2 treatments;
- •History of allergy or delayed allergic reaction to any component of study drug that is considered by the investigator to be more severe;
- •History of interstitial pneumonia/lung disease requiring steroid treatment;
- •The cumulative amount of previous exposure to anthracyclines has reached the certain dosage;
- •Treated with strong CYP3A inhibitors or strong CYP3A inducers within 14 days before the first dose of study drug or the presence of concurrent diseases requiring treatment with potent inhibitors or inducers of CYP3A4 during the study treatment;
- •History of severe corneal ophthalmopathy;
- •Peripheral neuropathy ≥ grade 3 (refer to NCI CTCAE 5.0);
- •Symptomatic and unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis;
Arms & Interventions
DP303c
Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
Intervention: DP303c
Outcomes
Primary Outcomes
Area Under Curve from t 0 to the infinity (AUC0-inf)
Time Frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
Area Under Curve from 0 to the last point (AUC0-last)
Time Frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
Time to Reach Peak Serum Concentration (Tmax)
Time Frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
Maximum Plasma Concentration [Cmax]
Time Frame: Day 1,2,3,8, and 15 of cycle 1 and 3, and day 1 of each following cycle (each cycle is 21 days)
Secondary Outcomes
- Incidence of adverse events (AEs)(Up to approximately 12 months)
- Objective Response Rate (ORR)(Up to approximately 12 months)
- Incidence of Neutralizing antibodies (Nab)(Day 1, 8, and 15 of cycle 1, and day 1 of each following cycle (each cycle is 21 days))
- Duration of Response (DoR)(Up to approximately 12 months)
- Disease control rate (DCR)(Up to approximately 12 months)
- Incidence of anti-drug antibodies (ADA)(Day 1, 8, and 15 of cycle 1, and day 1 of each following cycle (each cycle is 21 days))